SCHEMBL2256202

SCHEMBL2256202

CC(=O)SCCBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7879535 0.83
SCHEMBL10484076 0.81
SCHEMBL22551299 0.81 CYP2C19 (0.60)
SCHEMBL625045 0.79 CYP2C19 (0.43)
SCHEMBL22521141 0.79 CYP2C19 (0.43)
SCHEMBL5502050 0.79 CYP2C19 (0.43)
SCHEMBL30504176 0.79 CYP2C19 (0.43)
SCHEMBL8427233 0.79 CYP2C19 (0.43)
SCHEMBL19194532 0.79 CYP2C19 (0.43)
SCHEMBL12177996 0.79 CYP2C19 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743440-A1 IONIZABLE LIPIDS eTheRNA immunotherapies NV (BE) 2026-05-20 EP disclosed
WO-2025012376-A1 IONIZABLE LIPIDS ETHERNA IMMUNOTHERAPIES NV (BE) 2025-01-16 WO disclosed
EP-2114951-B9 NOVEL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2015-09-02 EP disclosed
CN-1738829-B New 2',5'-oligoadenylic acid analog SANKYO CO 2012-11-28 CN disclosed
US-7994152-B2 Method of treating a cancer by administering A 2′,5′-oligoadenylate analog SANKYO COMPANY, LIMITED (JP) 2011-08-09 US disclosed
US-20100035976-A1 Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-7651999-B2 phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer SANKYO COMPANY, LIMITED (JP) 2010-01-26 US disclosed
US-20090182011-A1 Chimeric Nitrate Esters and Use of the Same in a Treatment for Depression UNIVERSITY OF ILLINOIS CHICAGO (US) 2009-07-16 US disclosed
CN-1738829-A New 2',5'-oligoadenylic acid analog SANKYO CO (JP) 2006-02-22 CN disclosed
US-20050261235-A1 2' ,5' -Oligoadenylate analogs SANKYO COMPANY, LIMITED (JP) 2005-11-24 US disclosed
EP-0642520-A1 THIO-SUBSTITUTED CYCLIC PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM PROCTER & GAMBLE PHARMACEUTICALS (US) 1995-03-15 EP disclosed
US-5391743-A Treating osteoporosis, rheumatoid arthritis, osteoarthritis PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1995-02-21 US disclosed
WO-1993024498-A1 QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM AS WELL AS DENTAL CALCULUS AND PLAQUE PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1993-12-09 WO disclosed
WO-1993024499-A1 QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1993-12-09 WO disclosed
WO-1993024497-A1 THIO-SUBSTITUTED CYCLIC PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1993-12-09 WO disclosed
WO-1993024495-A1 PHOSPHONOSULFONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1993-12-09 WO disclosed
WO-1993024494-A1 QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS, FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM THE PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1993-12-09 WO disclosed
WO-1993024131-A1 PHOSPONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1993-12-09 WO disclosed
US-4487929-A HYPOTENSIVE AGENTS HOFFMANN-LA ROCHE, INC. (US) 1984-12-11 US disclosed
US-4399136-A Pyrazolopyridazine antihypertensives HOFFMANN-LA ROCHE INC. (US) 1983-08-16 US disclosed